SAGE Therapeutics Inc (SAGE) Stock Analysis
Verdict: AVOID
Investment score: 38/100
Analysis as of
Is SAGE Therapeutics Inc stock worth reviewing? The TradeMates thesis
SAGE is currently a value trap characterized by massive cash burn, shrinking revenue, and heavy insider selling, despite trading below book value.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 30/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 65/100 (weight 15%)
- Insider Sentiment: 10/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
SAGE Therapeutics Inc opportunities and risks
What speaks for SAGE
- Trading Below Book Value
What speaks against SAGE
- Aggressive Insider Selling
Peers and competitors
- KYTX
- OCGN
- STRO
- LYEL
- STTK
Frequently asked questions about SAGE Therapeutics Inc (SAGE)
Is SAGE stock a good investment?
The TradeMates model rates SAGE Therapeutics Inc as AVOID with an investment score of 38/100. SAGE is currently a value trap characterized by massive cash burn, shrinking revenue, and heavy insider selling, despite trading below book value. This is algorithmic model output, not personal investment advice.
Is SAGE stock a buy?
The TradeMates model verdict for SAGE is AVOID with an investment score of 38/100. Treat this as a model signal to review, not a personal buy recommendation.